Skip to main content

Table 4 Surgical breast and lymph node management for the FEC and PE arms

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Surgery type

FEC arm [cases (%)]

PE arm [cases (%)]

P value

Total

132

130

 

The breast

  

0.456

 Breast-conserving surgery

3 (2.27)

4 (3.08)

 

 Mastectomy

75 (56.82)

66 (50.77)

 

 Modified radical mastectomy

54 (40.91)

60 (46.15)

 

Lymph nodes

  

0.633

 No surgerya

0 (0.00)

1 (0.77)

 

 SLNBa

1 (0.76)

2 (1.54)

 

 Level I–II node dissection

28 (21.21)

21 (16.15)

 

 Level I–III node dissection

86 (65.15)

89 (68.46)

 

 Level I–III + supraclavicular node dissection

17 (12.88)

17 (13.08)

 
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, SLNB sentinel lymph node biopsy
  2. aRequired by participants